Verona Pharma Announces August 2021 Virtual Investor Conference Participation
07/27/2021 - 02:00 AM
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following virtual investor conferences in August 2021:
BTIG Virtual Biotechnology Conference
12th Annual Wedbush PacGrow Healthcare Virtual Conference
41st Annual Canaccord Genuity Growth Conference
A webcast of the Canaccord fireside chat will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com .
Verona Pharma plc US Tel: +1-833-417-0262 Victoria Stewart, Director of Investor Relations and Communications info@veronapharma.com Argot Partners Tel: +1-212-600-1902verona@argotpartners.com Kimberly Minarovich / Michael Barron Optimum Strategic Communications Tel: +44 (0)203 950 9144verona@optimumcomms.com Mary Clark / Karl Hard / Elakiya Rangarajah
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com .
VRNA Rankings
#1797 Ranked by Stock Gains
VRNA Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Medicinal and Botanical Manufacturing
Country
United Kingdom
City
3 More London Place
About VRNA
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
